Though tianeptine isn’t FDA-approved, it’s not illegal and can be purchased online as a dietary supplement. An apparent spike in the use of an unapproved antidepressant called tianeptine is poisoning people who are looking to benefit from the drug’s mild opioid-like effects, according to a Centers for Disease Control and Prevention (CDC) report released last… Continue reading Misuse Of Unapproved Antidepressant With Opioid-Like Effects Spikes
Tag: FDA
FDA Warns Of Synthetic Marijuana Laced With Rat Poison
The warning comes amid a wave of synthetic marijuana overdoses. The FDA warned this week about the ongoing danger of synthetic cannabis laced with rat poison, floating concerns that the tainted drug could pose a threat to the nation’s blood supply. Poisoned supplies of the drug have already accounted for several deaths and sent hundreds… Continue reading FDA Warns Of Synthetic Marijuana Laced With Rat Poison
FDA: Limiting Opioids Won't Curb Crisis, Responsible Prescribing Will
The FDA commissioner issued a statement addressing the stigma aimed at pain patients and the need for providers to take a patient-centric approach. Strict opioid prescribing regulations are harming some chronic pain patients, according to U.S. Food and Drug Administration Commissioner Scott Gottlieb. On Monday, July 9, the FDA released a statement about its Patient-Focused… Continue reading FDA: Limiting Opioids Won't Curb Crisis, Responsible Prescribing Will
Frustrated Pain Patients Meet With FDA About Opioid Access
A group of pain patients met at FDA headquarters to share their personal stories in a bid to get the agency to ease opioid restrictions. The FDA called a meeting in Washington, D.C. to listen to pain patients’ experiences of lacking access to opioids to manage their symptoms. A group traveled to the FDA’s headquarters… Continue reading Frustrated Pain Patients Meet With FDA About Opioid Access
Kratom Supporters Converge on Washington to Fight Potential Ban
Kratom advocates met at the U.S. Capitol in early June to begin a week of lobbying in favor of the substance. With a federal ban on kratom gaining traction in Washington, D.C, advocates of the plant’s pain management and potential opioid withdrawal properties traveled to the nation’s capital to lobby support for the Southeast Asian plant.… Continue reading Kratom Supporters Converge on Washington to Fight Potential Ban
Generic Suboxone Strips Get The Green Light
The FDA’s move could mean wider availability and more competitive pricing for the popular addiction-fighting drug. The FDA last week sparked a flurry of legal wrangling when it gave the go-ahead for two drugmakers to sell generic versions of Suboxone strips. Part of an agency push to expand access to medication-assisted treatment, the move could… Continue reading Generic Suboxone Strips Get The Green Light
New Generation Of Antidepressants On FDA Fast Track
The medications, which are still in development, may be able to help those who have not found success with currently available antidepressants. Pharmaceutical companies are honing in on the potential of ketamine and more to provide fast-acting antidepressant relief, Healthline reports. Two examples are Janssen Pharmaceuticals’ esketamine nasal spray and Allergan’s rapastinel (a different, but… Continue reading New Generation Of Antidepressants On FDA Fast Track
FDA Challenges Developers To Make Better Pain Treatment Devices
For an innovation challenge, the FDA is looking for devices that provide more benefits than opioids, with fewer risks. The Food and Drug Administration wants better options available for treating pain—and it is turning to developers for help. The FDA announced this week that it is running a new innovation challenge for medical devices that… Continue reading FDA Challenges Developers To Make Better Pain Treatment Devices